Home
overview

SMi’s 3rd Annual Conference
Superbugs & Superdrugs USA 
November 12 - 13, 2018 | Iselin, New Jersey
------------------------------------------------------------------------------------

The issue of antibacterial resistance is becoming increasingly prevalent within the world of modern medicine. Difficult-to-treat pathogens create an incredibly real issue within clinical environments; and the problem needs to be addressed with novel treatments and the development of mechanisms which circumvent current therapeutic barriers.The push to commercialization of novel anti-infectives is also a big barrier to market entry within the field; with red-tape and funding restrictions creating hindrances to the progress of anti-infective drugs through trial and regulatory approvals processes.

To address the ever-growing need of informative and thought provoking discussion, in order to address these industry issues, Superbugs & Superdrugs USA conference will offer a jam-packed agenda with presentations from key industry leaders and up-and-coming thinkers, within the field.

Register to attend by September 28 to save $100 on booking fee
 

LETTER FROM CHAIRS
"While recently approved antibiotic agents will likely help stem AMR crisis, novel approaches to the prevention and treatment of MDR infections are needed to ensure a viable antimicrobial armamentarium for the future.
The SMi's Superbugs & Superdrugs USA meeting will bring together expertise from individuals in multiple disciplines in the field of infectious disease representing research, regulatory, funding, diagnostics and academia to focus on supporting antimicrobial research and development, funding opportunities and resources for companies, new diagnostics for clinical applications, as well as novel therapies and approaches"

William J. Weiss - UNT System College of Pharmacy
A. Simon Lynch - Janssen Research & Development



 

By attending our 3rd annual Superbugs & Superdrugs USA event, not only would you benefit from the knowledge delivered through range of thought-provoking presentations, by experts at the forefront of the field; but you would also receive the opportunity to interact with and exchange ideas with decision makers from all of the different facets of the industry – from research to commercial providers and regulatory bodies

What our attendees said last year:

"Very interesting range of speakers and topics - really looking forward to the 2018 event!"

"The chairs did a great job of moderating - great discussion"

This year's Superbugs & Superdrugs USA Conference will help you to:

  • Gain insight into Diagnostic Technologies being used in the field and the futuristic developments which could be implemented.
  • Network with key industry leaders and benefit from though provoking discussions
  • Hear from the main regulatory bodies to advise on guidelines surrounding funding and development
  • Listen to up-and-coming companies, developing novel approaches to circumvent antibacterial resistance
  • Discover new approaches of anti-fungal development
  • Discuss CMC strategies for novel antibiotic drug development
  • Learn about the challenges and solutions to successful commercialization of new antibiotics

Achaogen Inc; Amplyx Pharmaceuticals, Inc; Battelle; Centauri Therapeutics; CLINIC; ContraFect; ContraFect Corporation; DeNovaMed Inc; Emergent BioSolutions; Emergent BioSolutions Inc.; Evotec; F2G Ltd; FDA; Forge Therapeutics, Inc.; FUJIFILM Diosynth Biotechnologies; HHS/ASPR/BARDA; Janssen Research & Development, LLC; Laboratoire Biodim; Lovelace Respiratory Research Institute; Macrolide Pharmaceuticals, Inc.; MDLinx; Mdlinx Inc; MedImmune; Merck; Merck & Co.; Microbiotix Inc; Micromyx LLC; Micron Research; Morton Findlay Associates Ltd; Motif BioSciences; N8 Medical LLC; NeoSome Life Sciences, LLC; Nobelex Biotech; Novo AS; Pfizer; Prodigy Biotechnology; Rutgers University; Social & Scientific Systems Inc; Soligenix, Inc.; Teleflex; UNT Health Science Center; UNTHSC; Visterra; Weber Shandwick;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

William Weiss

William Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center

9:10 Discovery and evaluation of inhibitors of intermediary metabolism as novel antibiotics against Gram-negative bacterial pathogens

Brent Cezairliyan

Brent Cezairliyan, Senior Scientist, Octagon Therapeutics
View Bio

  • Identification of growth conditions that stimulate virulence of the human pathogen Pseudomonas aeruginosa
  • A screening platform to identify novel compounds that inhibit bacterial growth under virulence-stimulating conditions
  • Inhibitors of central metabolism exhibit in vivo activity against P. aeruginosa and Acinetobacter baumannii infections
     
  •  

    9:50 Pathogen-focused drug development: buyer beware

    Ian Friedland

    Ian Friedland, Clinical Consultant, Ex-Chief Medical Officer, Achaogen
    View Bio

  • The development of new antimicrobial agents following current regulatory pathways remains challenging if the development is aimed at addressing resistant or single species gram negative pathogens
  • The recent passage of LPAD (limited population antimicrobial drug) pathway legislation raised the promise of greater flexibility in accepting smaller datasets for approval of drugs addressing an uncommon unmet need
  • However, what this means in practical terms is still unclear 
  • Recent experience with the development and approval of plazomicin for an unmet need indication has been disappointing and will be discussed 
     
  • 10:30 Morning Coffee

    11:00 Overcoming bacterial resistance through a novel mode of action

    Malcolm Thomas

    Malcolm Thomas, CEO, Agile Sciences
    View Bio

  • A new class of 2-aminoamidazole molecules that inhibit bacterial protection mechanisms
  • Disperse and inhibit biofilm formation
  • Lowers effective dose of antibiotic
     
  • 11:40 VNRX-5133: a highly potent and broad-spectrum inhibitor of both serine and metallo beta-lactamases

    Daniel Pevear

    Daniel Pevear, Sr. Vice President of Biology and Grants Development, Venatorx Pharmaceuticals
    View Bio

  • VNRX-5133 is a boronic acid that exhibits direct, selective and potent inhibitory activity against bacterial serine and metallo-b lactamases
  • VNRX-5133 rescues cefepime activity in strains of ESBL- and carbapenemase-expressing Enterobacteriaceae and Pseudomonas aeruginosa
  • VNRX-5133 is a b-lactamase inhibitor that lacks stand-alone antibacterial activity
  • VNRX-5133 rescues cefepime activity in vivo in multiple animal models of bacterial infection
  • 12:20 Networking Lunch

    13:30 TP-6076: A novel fluorocycline antibiotic with potent activity against carbapenem-resistant Gram (-) organisms

    Joe Newman

    Joe Newman, Senior Director, Head of Biology, Tetraphase Pharmaceuticals
    View Bio

  • TP-6076 is a potent inhibitor of bacterial protein synthesis
  • The activity of TP-6076 is not affected by the common mechanisms of Gram (-) resistance
  • TP-6076 demonstrates potent activity in murine thigh and lung infections
  • 14:10 Iclaprim, an antibiotic differentiated from other antibiotics for serious and life-threatening infections

    Stephanie Noviello

    Stephanie Noviello, V.P Clinical Development, MotifBio
    View Bio

  • Activity against nonsusceptible MRSA isolates to standard of care antibiotics
  • Concentration at sites of infection
  • Suppresses bacterial toxin production
  • Not nephrotoxic, no renal dosing or therapeutic drug monitoring required
  • 14:50 Immunotherapeutics targeting Pseudomonas aeruginosa acute and persistent infections

    Antonio DiGiandomenico

    Antonio DiGiandomenico, Principal Scientist, MedImmune
    View Bio

  • Introduce novel anti-Pseudomonal mAbs and their mechanisms of action
  • Activity will be discussed in multiple animal models when used in both prophylaxis and treatment indications
  • Activity against biofilms will also be presented
  • Synergy with antibiotic treatment will also be discussed
  • 15:30 Afternoon Tea

    16:00 The state of developments within the anti-fungal space

    Mahmoud Ghannoum

    Mahmoud Ghannoum, Director of Center for Medical Mycology, Case Western Reserve University
    View Bio

  • What is the status of resistance in terms of fungal pathogens?
  • What are the main fungal strains posing the greatest threat to public health?
  • Which are the current anti-fungals currently in use?
  • Where are the gaps in anti-fungal development, which need to be addressed?
  • 16:40 SCY-078: A first-in-class, orally-bioavailable, glucan synthase inhibitor has broad spectrum activity against Candida, Aspergillus and Pneumocystis spp

    Stephen Barat

    Stephen Barat, Head of Pre-Clinical and Early Clinical Development, SCYNEXIS Inc
    View Bio

  • Effects of SCY-078 against multi-drug resistant fungal pathogens
  • Results from preclinical PK/PD models for Candida, Aspergillus and Pneumocystis spp
  • Discussion on pharmacokinetic characteristics of SCY-078, including disposition profile
  • Applications in the treatment of life-threatening infections
  • 17:20 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Anthony Simon Lynch

    Anthony Simon Lynch, Senior Scientific Director, Janssen Fellow & Incubator Leader, Janssen

    9:10 The Microbiome and its impact on the field

    Christopher Ford

    Christopher Ford, Group Leader, Microbiome Sciences of ID, Seres Therapeutics

  • An overview of the current research being done into the microbiome, with applications to antimicrobial development
  • Anti-pathogenic properties of certain substances being produced by some microbes
  • A case study of clostridium difficile infections – an imbalance in the gut microbiome
  • 9:50 Supporting antibacterial research and development

    Mark Albrecht

    Mark Albrecht, Project Officer, HHS/ASPR/BARDA

  • What is BARDA and why is it interested in AMR
  • How BARDA partners with industry to stimulate innovation in AMR R&D
  • How CARB-X is refilling the preclinical AMR product pipeline
     
  • 10:30 Morning Coffee

    11:00 CMC strategies for novel antibiotic drug development

    Evan Hecker

    Evan Hecker, Director of API Development, Spero therapeutics

  • The start to finish process within chemical development – an all-encompassing overview
  • Considerations for oral drug products and parenteral formulations
  • Pre-commercial CMC development, how not to be consumed by CTM deliverables
  • NDA-enabling CMC studies are critical
  • Audit processes of a manufacturing facility – issues and stumbling blocks and obvious red flags
     
  • 11:40 NIAID funding and resources for development of anti-infectives

    Anita Sheoran

    Anita Sheoran, Therapeutics Development Project Officer, NIAID, NIH
    View Bio

  • NIAID strategic plan for CARB and support for development of novel therapeutic classes
  • Overlapping funding strategies and a broad spectrum of preclinical and clinical services that educe product development risk
  • Current funding and partnership opportunities for development of antibacterials. 
  • 12:20 Networking Lunch

    13:30 Update on epidemiology, resistance and treatments of GI related infectious disease

    William Weiss

    William Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center

  • Advances in the diagnosis and treatment of Clostridium difficile infections
  • Helicobacter pylori - Latest research and news
  • Drug-resistant intestinal bugs - Salmonella, Shigella, and Yersinia
  • Gut microbiome: a new player in gastrointestinal disease
  • 14:10 Practical clinical diagnostic applications using laser light-scattering: utility, adoption, and opportunities

    Andrew Tomaras

    Andrew Tomaras, VP and Director of Microbiology, BacterioScan Inc.
    View Bio

  • Production of accurate and affordable platform for widespread clinical use
  • Performance of current clinical application for rapid urinary tract infection detection
  • Developmental applications including other direct-from-specimen infection detection and phenotypic antimicrobial susceptibility testing
  • Platform utilization to streamline new antimicrobial clinical trial enrolment and clinical adoption
  • 14:50 Afternoon Tea

    15:20 Next-generation point of care diagnostic solutions: a new era of clinical performance

    Sachin Garg

    Sachin Garg, Director of Clinical Science, Roche Molecular Systems, Inc
    View Bio

  • Traditional POC diagnostics are often hindered by poor quality assurance and test performance compared to laboratory-based tests.
  • Recent innovations have led to the introduction of molecular POC diagnostics in infectious diseases, however important considerations and challenges remain.
  • Next-generation POC diagnostic solutions will play an important role in delivering high-quality clinical care and reducing overall healthcare expenditures.
  • Roche’s cobas® Liat® System is one example that brings real-time PCR technology to the POC to provide the performance, quality, and automation of laboratory-based solutions.
     
  • 16:00 BACLIB - where lipid-based mass spectrometry phenotyping outperforms current protein-based microbial diagnostics

    Robert Ernst

    Robert Ernst, Professor and Vice Chair Bacterial Pathogenesis, University Of Maryland
    View Bio

  • Microbial membrane glycolipids represent a unique diagnostic target
  • Diagnostic potential directly from clinically relevant material, including blood bottles, urine
  • Applicable for polymicrobial samples from simple or complex samples and reveals patterns of antimicrobial resistance
  • Rapid, microbial identification in less than 60 minutes direct from specimen
  • 16:40 Pharmacokinetic and Pharmacodynamic approaches to optimize drug development in invasive Aspergillosis

    Laura Kovanda

    Laura Kovanda, Senior Director Global Development Project Leader, Astellas Pharma Global Development, Inc.

    PK-PD techniques to better estimate dosage regimens
    Validation of preclinical models and controls to be used for future compounds in IA
    Possibility of using biomarker as endpoints in clinical trials of IA
     

     

    17:20 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Andrew Tomaras

    Andrew Tomaras

    VP and Director of Microbiology, BacterioScan Inc.
    Antonio DiGiandomenico

    Antonio DiGiandomenico

    Principal Scientist, MedImmune
    Brent Cezairliyan

    Brent Cezairliyan

    Senior Scientist, Octagon Therapeutics
    Ian Friedland

    Ian Friedland

    Clinical Consultant, Ex-Chief Medical Officer, Achaogen
    Mark Albrecht

    Mark Albrecht

    Project Officer, HHS/ASPR/BARDA

    Andrew Tomaras

    VP and Director of Microbiology, BacterioScan Inc.
    Andrew Tomaras

    Dr. Tomaras is currently Vice President and Director of Microbiology at BacterioScan, Inc, where his roles include new product/protocol development and the design and oversight of clinical regulatory activities. He received his BA and PhD degrees from the Department of Microbiology at Miami University in 2000 and 2004, respectively. His subsequent postdoctoral research was conducted at the University of Colorado Health Sciences Center. He joined the Antibacterials Research Unit at Pfizer in 2008, and helped to start the Endogenous Human Biologic Response group as a Senior Principal Scientist within the Biotherapeutics Division in 2011.

    Anita Sheoran

    Therapeutics Development Project Officer, NIAID, NIH
    Anita Sheoran

    Anita Sheoran is Program Officer at NIAID’s Drug Development Section in Division for Microbiology and Infectious Diseases where she provides technical and business oversight of a multimillion-dollar antibacterial drug development portfolio of NIAID funded contracts. She is NIAID’s liaison to CARB-X and serves as a member of its Scientific Review Boards. Also, she serves as steering committee member of Defense health funded wound infection prevention and management task area at Military Infectious Diseases Research Program. Prior to joining NIAID, she held several positions in public and private sector supporting pre-clinical to the early clinical phase development of drugs against multi-drug resistant bacteria and fungi

    Anthony Simon Lynch

    Senior Scientific Director, Janssen Fellow & Incubator Leader, Janssen
    Anthony Simon Lynch

    Antonio DiGiandomenico

    Principal Scientist, MedImmune
    Antonio DiGiandomenico

    Dr. Antonio DiGiandomenico is currently a Principal Scientist in the Department of Microbial Sciences at MedImmune/AstraZeneca and has 20 years of experience in microbiology and immunology. Dr. DiGiandomenico began his training in molecular biology and microbial pathogenesis at Duquesne University and continued his doctoral training at the University of Virginia. Upon completion of a postdoctoral fellowship at Vanderbilt University, Dr. DiGiandomenico accepted a position at MedImmune in 2009. Since arriving at MedImmune, Dr. DiGiandomenico has focused on the development of novel immunotherapeutics against multi-drug resistant bacteria in multiple disease settings and has contributed to pre-clinical and clinical programs.

    Brent Cezairliyan

    Senior Scientist, Octagon Therapeutics
    Brent Cezairliyan

    Dr. Cezairliyan is Vice President of Microbiology at Octagon Therapeutics. He has studied bacterial pathogenesis as a geneticist and a biochemist for over 15 years. Prior to Octagon, Dr. Cezairliyan worked at Massachusetts General Hospital and Harvard Medical School where he studied the regulation of bacterial virulence under fellowships from the NIH and the Cystic Fibrosis Foundation. Dr. Cezairliyan received his Ph.D. from the Massachusetts Institute of Technology, where he studied signaling mechanisms in bacterial proteostasis.

    Christopher Ford

    Group Leader, Microbiome Sciences of ID, Seres Therapeutics
    Christopher Ford

    Daniel Pevear

    Sr. Vice President of Biology and Grants Development, Venatorx Pharmaceuticals
    Daniel Pevear

    Dr. Pevear is the Senior Vice President of Biology and Grants Development at VenatoRx Pharmaceuticals Incorporated, which he co-founded in 2010 with Drs. Christopher Burns (CEO) and Luigi Xerri (CDO). Dr. Pevear has over 30 years of experience in both biotech and big pharma, with stints at Sterling Winthrop, ViroPharma (co-founder), Progenics, Novartis and Protez Pharmaceuticals. He received in Ph.D. in 1984 from Rensselaer Polytechnic Institute in Viral Immunology, and was a Multiple Sclerosis Post-Doctoral Fellow at Northwestern University Medical School with Dr. Howard Lipton. Dr. Pevear has over 60 peer-reviewed publications and has co-authored several book chapters.

    Evan Hecker

    Director of API Development, Spero therapeutics
    Evan Hecker

    Ian Friedland

    Clinical Consultant, Ex-Chief Medical Officer, Achaogen
    Ian Friedland

    Dr. Friedland is currently a consultant, focusing on advising companies on early and late development of anti-infective products. He trained as a pediatric infectious disease specialist at UT Southwestern Medical Center in Dallas. He served as the chief medical officer at Achaogen from 2014 to 2017, where he was responsible for leading the clinical development, regulatory strategy and medical affairs functions. Prior to Achaogen, Dr. Friedland headed the clinical development of numerous antibiotics at Cubist pharmaceuticals. He has worked in the pharmaceutical and biotechnology industry for 20 years, at both large Pharma (Merck, J&J) and several small biotech companies, leading clinical development teams of several important antibiotics and has played a pivotal role in the submission in the US, EU and other regions of drugs including ertapenem, caspofungin, doripenem, alvimipan, fidaxomicin, ceftolozane/tazobactam and plazomicin, in addition to supporting many marketed anti-infective agents. He is a frequent participant in a number of FDA/FNIH/PhRMA infectious disease working groups. He is an author on over 100 peer reviewed journal articles and book chapters.

    Joe Newman

    Senior Director, Head of Biology, Tetraphase Pharmaceuticals
    Joe Newman

    Dr. Newman, has over 25 years of experience in the fields of microbiology, animal model development and pharmacology. Prior to joining Tetraphase, Dr. Newman worked at Triad Therapeutics and AstraZeneca. During this period, he was involved in four programs which are currently in clinical development. Dr. Newman was also responsible for new model development at AstraZeneca, including in vivo models of MDR/XDR Enterobacteriaceae spp. and A. baumannii. During his tenure at Tetraphase Dr. Newman has been responsible for writing the nonclinical section of the Eravacycline NDA and MAA submissions, and is the principal Investigator on the TP-6076 CARB-X grant.

    Laura Kovanda

    Senior Director Global Development Project Leader, Astellas Pharma Global Development, Inc.
    Laura Kovanda

    Mahmoud Ghannoum

    Director of Center for Medical Mycology, Case Western Reserve University
    Mahmoud Ghannoum

    Dr Mahmoud Ghannoum received MSc in Medicinal Chemistry and PhD in Microbial Physiology from University of Technology in England, and an MBA from the Weatherhead School of Management at Case. Presently he is a tenured Professor and Director of the Center for Medical Mycology, Case Western Reserve University and University Hospitals Case Medical Center (UH) where he established a multidisciplinary disciplinary Center of Excellence that combines basic and translational research investigating microbes from the test tube to the bedside. He is also a fellow of the Infectious Disease Society of America and past President of the Medical Mycological Society of the Americas (MMSA). In 2016, Dr Ghannoum received the Rohda Benham Award presented for his continuous outstanding and meritorious contributions to medical mycology from the Medical Mycological Society of the Americas and he also received the Freedom to Discover Award from Bristol-Myers Squibb for his work on microbial biofilms.

    Malcolm Thomas

    CEO, Agile Sciences
    Malcolm Thomas

    Before joining Agile Sciences Mr. Thomas was president and CEO of Arbovax, a biotechnology company commercializing a unique and innovative platform technology that can be used to make vaccines against insect-borne viral diseases. Prior to Arbovax he was Vice President of Operations for StemCo Biomedical and before that, was Director of International Marketing for Bayer Biologicals and Vice President of Pacific Rim Operations for Becton Dickinson Biosciences. During his tenure with Becton Dickinson as Vice President for Asia Pacific he lived in Singapore for 5 years. He started his working life as a research scientist in the biochemistry department of the Wellcome Research Laboratories in the UK.

    Mark Albrecht

    Project Officer, HHS/ASPR/BARDA
    Mark Albrecht

    Robert Ernst

    Professor and Vice Chair Bacterial Pathogenesis, University Of Maryland
    Robert Ernst

    He is a Professor and Vice Chair in the Department of Microbial Pathogenesis at the University of Maryland – Baltimore. His laboratory is focused on elucidating the molecular basis by which bacteria and fungi modify the lipid component of their membrane and how these alterations affect normal host innate immune system responses. Additionally, the observed lipid diversity constitutes a “chemical barcode or fingerprint” that can be used to rapidly identify pathogens by mass spectrometry profiling from a variety of samples, such as solid medium plates and clinically obtained patient samples including blood bottles and urine.

    Sachin Garg

    Director of Clinical Science, Roche Molecular Systems, Inc
    Sachin Garg

    Dr. Sachin Garg, MD, MAS, is a Director of Clinical Science at Roche Molecular Systems, focusing on molecular point of care diagnostics. He joined Roche from the University of California, San Francisco, where he was on faculty and completed an NIH-funded postdoctoral research fellowship. Dr. Garg attended Emory University School of Medicine and completed Internal Medicine residency at the Hospital of the University of Pennsylvania. He has frontline experience in primary care at the Palo Alto Medical Foundation and working as an EMT. Dr. Garg studied Economics at Northwestern University and worked as a management consultant for Oliver Wyman Consulting

    Stephanie Noviello

    V.P Clinical Development, MotifBio
    Stephanie Noviello

    Stephanie Noviello joined Motif Bio in May 2018 from Bristol-Myers Squibb, where she was the Virology Clinical Program Lead for the hepatitis B, hepatitis C and HIV portfolios. She previously worked at Schering-Plough Research Institute in Hepatology. Prior to working in industry, she was an Epidemic Intelligence Service Officer at the Centers for Disease Control and Prevention stationed with the New York State Department of Health Bureau of Communicable Disease Control. She is a board-certified pediatrician, and received her M.D. from Tulane University School of Medicine and her M.P.H. from the Tulane University School of Public Health and Tropical Medicine.

    Stephen Barat

    Head of Pre-Clinical and Early Clinical Development, SCYNEXIS Inc
    Stephen Barat

    Stephen A. Barat, PhD, is currently the Head of Preclinical Research and Early Development for Scynexis. Dr. Barat has more than 20 years of global drug development and registration experience across multiple therapeutic areas. Prior to joining Scynexis, he served in various leadership positions in preclinical development in Allergan, Forest Laboratories, and Schering-Plough. Dr. Barat is also a recognized expert in the interface between safety assessment and CMC requirements and is a member of the PQRI working group for leachables from parenteral drug products and the USP expert panel on biocompatability of packaging materials. He has spoken extensively in numerous international venues on a variety of topics on drug development.

    William Weiss

    Director of Pre-Clinical Services, University of North Texas Health Science Center
    William Weiss

    Sponsors and Exhibitors

    Official Media Partner

    Official Associations

    Supporting Media Partners

    Workshops

    Rapid diagnostics for drug resistance: Are we there yet?
    Workshop

    Rapid diagnostics for drug resistance: Are we there yet?

    Renaissance Woodbridge Hotel
    14th November 2018
    Iselin, USA

    VENUE

    Renaissance Woodbridge Hotel

    515 US Highway 1 South, Iselin, New Jersey, USA

    Your simple delights will become memorable moments at Renaissance Woodbridge Hotel. This distinctive hotel in Edison, New Jersey, features 269 modern guest rooms, including 42 suites, and more than 25,000 square feet of flexible meeting space. Our hotel's location is centrally located amidst corporate offices and tourist attraction. Our accommodations stand out from other hotels in Edison, NJ, and provide a sophisticated retreat for families and business travelers alike. Marriott's Plug-in panels and 37-inch LCD HD TVs allow guests simultaneous connectivity to laptops, iPods and DVD players. We are one of the most conveniently situated hotels at the crossroads of U.S. Routes 1 and 9. We are also just five minutes from Woodbridge Center Mall, 15 minutes south of Newark Liberty International Airport (EWR) and less than one mile from the Metropark train station. With our premier location and amenities, our Edison accommodations provide an advantageous travel destination.

    HOTEL BOOKING FORM

    Infographic for Superbugs & Superdrugs USA

    Download

    Interview with Dr. Brent Cezairliyan - Octagon Therapeutics

    Download

    Interview - Stephanie Noviello, Motif Bio

    Download

    Interview with Laura Kovanda, Astellas Pharma Global Development, Inc.

    Download

    Presentation by Cara Cassino, ContraFect

    Download

    Presentation by William J. Weiss, University of North Texas Health Science Center

    Download

    Presentation by Richard Alm, Macrolide Pharmaceuticals

    Download

    Presentation by Christopher McMaster, DeNovaMed

    Download

    Presentation by Nicole Mahoney, Merck

    Download

    Presentation by Mark Albrecht, BARDA

    Download

    [Interview] - Daniel Pevear, Venatorx Pharmaceuticals

    Download

    [Interview] - Mark Albrecht, HHS/ASPR/BARDA

    Download

    [Programme] - Superbugs & Superdrugs USA

    Download

    [Speaker Line-up]

    Download

    [LETTER FROM CHAIRS]

    Download

    [Attendee list]

    Download

    [Workshop A] - Programme

    Download

    [Workshop B] - Programme

    Download

    Sponsors and Exhibitors


    SCYNEXIS

    Sponsors and Exhibitors
    http://www.scynexis.com

    SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, SCY-078, is a novel IV/oral antifungal agent in Phase 2 clinical and preclinical development for the treatment of several serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.

    Media Partners


    American Pharmaceutical Review

    Official Media Partner
    http://www.americanpharmaceuticalreview.com

    Start receiving your free copy today. American Pharmaceutical Review is a review of the drug pipeline from the late discovery phase through manufacturing. American Pharmaceutical Review prides itself on having the most relevant, unbiased and informative editorial in the industry. You will find that all of our editorial is highly technical and written by government agencies, consultants, academics, and large pharmaceuticals companies. American Pharmaceutical Review covers several key topics that are important to drug production:Separations and purification, Drug Delivery, Biopharmaceutical Processing, Biopharmaceutical Development, Formulation development, Manufacturing, Microbiology, Instrumentation, Spectroscopy

    Media Partners


    American Laboratory

    Supporting Media Partners
    http://www.americanlaboratory.com

    For laboratory managers and researchers utilizing analytical chemistry and its applications, seeking knowledge on new technologies, methods, applications, and products, the American Laboratory® publication platform provides comprehensive technology coverage for laboratory professionals at all stages of their careers. Unlike single-channel publications, American Laboratory® is a multidisciplinary resource that engages scientists through print, digital, mobile, multimedia, and social channels to provide practical information and solutions for cutting-edge results. American Laboratory® serves the need of global community of laboratory professionals for communicating relevant technical advances and insights. Globally, American Laboratory® reaches out to subscribers by offering digital distribution plus premium print in North America. Digital communications utilize internet, mobile and social channels.


    Gate2Biotech

    Supporting Media Partners
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


    IPI

    Supporting Media Partners
    http://www.ipimediaworld.com

    IPI – International Pharmaceutical Industry Established by professionals with over 30 years experience in the Pharmaceutical and Life sciences publishing sectors. We have identified the needs of these dynamic industries, and have listened carefully to our readers and advertisers. With strong collaboration between Pharmaceutical and Life sciences Industry Associations we have created a global distribution network. We give you a promise to become a reliable extension of your marketing and communication arm. If necessary we will integrate our expertise with your needs. Incorporating new and innovative communication methods we will help to highlight your expertise.


    Technology Networks

    Supporting Media Partners
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Biocompare

    Supporting Media Partners
    http://www.biocompare.com

    Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.


    Rapid Microbiology.com

    Supporting Media Partners
    http://www.rapidmicrobiology.com

    rapidmicrobiology.com - keep up-to-date with all the latest products for your pharmaceutical microbiology laboratory, subscribe to the rapidmicrobiology.com newsletter http://www.rapidmicrobiology.com/Newsletter.php


    Pharmalicensing

    Supporting Media Partners
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc


    Drug Discovery Today

    Supporting Media Partners
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.
    Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.


    Infectious Diseases Hub

    Supporting Media Partners
    http://www.id-hub.com

    Infectious Diseases Hub is a free-to-access website open to all researchers, students and anyone else who might have an interest in the many aspects of microbiology and virology. We offer easy access to breaking news, interviews, opinion pieces, peer-reviewed articles and multimedia features, with a strong focus on the rising issue of antimicrobial resistance. Microbiology is such a diverse and exciting area, and with the emergence of new technologies giving us the ability to study complex communities and rapidly sequence whole genomes, there has been something of a ‘revolution’. Keeping on top of such technological advances and the latest emerging diseases is at the heart of Infectious Diseases Hub, and you can take a look at up-to-date essential research and information on the site now.


    Pharma Journalist

    Supporting Media Partners
    http://www.pharmajournalist.com

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.


    Global Biodefense

    Supporting Media Partners
    http://www.globalbiodefense.com/

    Global Biodefense publishes the latest news on vaccine and therapeutics countermeasure development, biosurveillance and detection technologies, food safety and biosecurity, and CBRN incident preparedness and response. Visit our website to access daily news updates, organization profiles, conference listings, and the latest in funding opportunities for advancing biodefense technology.


    Pharmaceutical Outsourcing

    Supporting Media Partners
    http://www.pharmoutsourcing.com

    Pharmaceutical Outsourcing, the journal dedicated to pharmaceutical and biopharmaceutical contract services. With regular sections on contract manufacturing, contract research, contract packaging, formulation/development services, contract analytical testing, APIs, stability testing, clinical research and other areas, we bring the most complete coverage of trends and issues in the industry to our 15,000 readers in North America.


    World Pharma News

    Supporting Media Partners
    http://www.worldpharmanews.com/



    pharmaphorum

    Supporting Media Partners
    http://www.pharmaphorum.com

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com

    Official Associations


    Swiss Biotech Association

    Official Associations
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Renaissance Woodbridge Hotel

    515 US Highway 1 South
    Iselin 08830
    USA

    Renaissance Woodbridge Hotel

    Your simple delights will become memorable moments at Renaissance Woodbridge Hotel. This distinctive hotel in Edison, New Jersey, features 269 modern guest rooms, including 42 suites, and more than 25,000 square feet of flexible meeting space. Our hotel's location is centrally located amidst corporate offices and tourist attraction. Our accommodations stand out from other hotels in Edison, NJ, and provide a sophisticated retreat for families and business travelers alike. Marriott's Plug-in panels and 37-inch LCD HD TVs allow guests simultaneous connectivity to laptops, iPods and DVD players. We are one of the most conveniently situated hotels at the crossroads of U.S. Routes 1 and 9. We are also just five minutes from Woodbridge Center Mall, 15 minutes south of Newark Liberty International Airport (EWR) and less than one mile from the Metropark train station. With our premier location and amenities, our Edison accommodations provide an advantageous travel destination.

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out